HIPK4: A Potential Drug Target and Biomarker for Human Disease

Target Name: HIPK4

NCBI ID: G147746

HIPK4

HIPK4: A Potential Drug Target and Biomarker for Human Disease

Hipk4, a member of the protein kinase family 4 (PK4), is a non-catalytic protein that plays a critical role in the regulation of cellular processes, including cell growth, differentiation, and survival. HIPK4 has been implicated in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. As a result, it has become an attractive drug target and a potential biomarker for these conditions. In this article, we will discuss the biology of HIPK4, its functions in disease, and its potential as a drug target and biomarker.

Biogenesis and Localization

HIPK4 is a 21-kDa protein that is expressed in various cell types, including neurons, macrophages, and breast cells. It is primarily localized to the cytoplasm and is also found in the nucleus, where it interacts with other transcription factors, including activator protein 1 (AP-1), p21 (TNF-伪), and p53. HIPK4 has been shown to play a role in the regulation of cellular processes, including cell growth, apoptosis, and transcriptional regulation.

Function and Interaction

HIPK4 is a key regulator of the homeodomain, which is a region of the protein that interacts with DNA to control gene expression. It is known to interact with various DNA-binding proteins, including p300, MLL-1, and p53. HIPK4 has been shown to play a role in the regulation of gene expression and has been linked to the development of various diseases.

In cancer, HIPK4 has been shown to promote the growth and survival of cancer cells. For example, HIPK4 has been shown to enhance the sensitivity of human breast cancer cells to chemotherapy. Additionally, HIPK4 has been shown to promote the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Drug Target Potential

HIPK4 is a potential drug target due to its role in the regulation of cellular processes and its involvement in various diseases. Drugs that target HIPK4 have been shown to have therapeutic effects in various disease models, including cancer, neurodegenerative diseases, and developmental disorders.

One of the most promising drugs that target HIPK4 is a small molecule inhibitor, called 纬-secretase inhibitor (GSI), which is a potent inhibitor of HIPK4. GSI has been shown to have therapeutic effects in various disease models, including cancer, neurodegenerative diseases, and developmental disorders.

Biomarker Potential

HIPK4 has also been shown to be a potential biomarker for various diseases. For example, HIPK4 has been shown to be overexpressed in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Additionally, HIPK4 has been shown to be a potential target for diagnostic biomarkers.

Conclusion

In conclusion, HIPK4 is a non-catalytic protein that plays a critical role in the regulation of cellular processes and has been implicated in various diseases. Its functions as a drug target and biomarker make it an attractive target for research and development of new therapies. The inhibition of HIPK4 by small molecules, such as GSI, has shown promise in the treatment of various diseases. Further research is needed to fully understand the role of HIPK4 in disease and its potential as a drug target and biomarker.

Protein Name: Homeodomain Interacting Protein Kinase 4

Functions: Protein kinase that phosphorylates human TP53 at Ser-9, and thus induces TP53 repression of BIRC5 promoter (By similarity). May act as a corepressor of transcription factors (Potential)

The "HIPK4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HIPK4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets